1. bookVolume 67 (2017): Edizione 1 (March 2017)
Dettagli della rivista
License
Formato
Rivista
eISSN
1846-9558
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Accesso libero

Switching antipsychotics: Results of 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders

Pubblicato online: 21 Feb 2017
Volume & Edizione: Volume 67 (2017) - Edizione 1 (March 2017)
Pagine: 99 - 112
Accettato: 20 Aug 2016
Dettagli della rivista
License
Formato
Rivista
eISSN
1846-9558
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese

1. J. M. Davis and S. Leucht, Commentary on strategies for switching antipsychotics, BMC Med. 6 (2008) 18-18; DOI: 10.1186/1741-7015-6-18.10.1186/1741-7015-6-18245313318590521Search in Google Scholar

2. N. H. Covell, C. T. Jackson and E. M. Weissman, Health monitoring for patients who have schizophrenia. Summary of the Mount Sinai conference recommendations, Postgrad. Med., Sept. 2006, Spec. No. 20-26.Search in Google Scholar

3. J. M. Kane, S. Leucht, D. Carpenter and J. P. Docherty, The expert consensus guideline series, optimizing pharmacologic treatment of psychotic disorders, introduction: methods, commentary, and summary, J. Clin. Psychiat. 64 (Suppl. 12) (2003) 5-19.Search in Google Scholar

4. P. J. Weiden, Discontinuation and switching antipsychotic medications: understanding the CATIE schizophrenia trial, J. Clin. Psychiat. 68 (Suppl. 1) (2007) 12-19.Search in Google Scholar

5. R. A. Rosenheck, S. Davis, N. Covell, S. Essock, M. Swartz, S. Stroup, J. McEvoy and J. Lieberman, Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial, Schizophr. Res. 107 (2009) 22-29; DOI: 10.1016/j.schres.2008.09.031.10.1016/j.schres.2008.09.03118993031Search in Google Scholar

6. S. Bazire, Psychotropic Drug Directory: The Professional’s Pocket Handbook and Aide Memoire, Health- Comm UK, Aberdeen 2010.Search in Google Scholar

7. P. M. Haddad and A. Wieck, Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management, Drugs 64 (2004) 2291-2314.Search in Google Scholar

8. D. D. Miller, Atypical antipsychotics: sleep, sedation and efficacy, Prim. Care Comp. J. Clin. Psychiat. 6 (2004) 3-7.10.4088/PCC.v06n0101Search in Google Scholar

9. C. H. Hennekens, A. R. Hennekens, D. Hollar and D. E. Casey, Schizophrenia and increased risks of cardiovascular disease, Am. Heart J. 150 (2005) 1115-1121; DOI: 10.1016/j.ahj.2005.02.007.10.1016/j.ahj.2005.02.00716338246Search in Google Scholar

10. M. Dossenbach, Y. Dyachkova, S. Pirildar, M. Anders, A. Khalil, A. Araszkiewicz, T. Shakhnovich, A. Akram, J. Pecenak, M. McBride and T. Treuer, Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study, Eur. Psychiat. 21 (2006) 251-258; DOI: 10.1016/j.eurpsy.2005.12.005.10.1016/j.eurpsy.2005.12.00516530390Search in Google Scholar

11. J. W. Newcomer and D. W. Haupt, The metabolic effects of antipsychotic medications, Can. J. Psychiat. 51 (2006) 480- 491.10.1177/07067437060510080316933585Search in Google Scholar

12. S. M. Stahl, Stahl’s Essential Psychopharmacology, Cambridge University Press, Cambridge 2009.Search in Google Scholar

13. J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S. Keefe, S. M. Davis, B. D. Lebowitz, J. Severe, J. K. Hsiao and clinical antipsychotic trials of intervention effectiveness (CATIE) investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N. Engl. J. Med. 353 (2005) 1209-1223; DOI: 10.1056/NEJMoa051688.10.1056/NEJMoa05168816172203Search in Google Scholar

14. P. Chue, The relationship between patient satisfaction and treatment outcomes in schizophrenia, J. Psychopharmacol. 20 (Suppl. 6) (2006) 38-56; DOI: 10.1177/1359786806071246.10.1177/135978680607124617046986Search in Google Scholar

15. J. M. Haro and L. Salvador-Carulla, The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia, CNS Drugs 20 (2006) 293-301.Search in Google Scholar

16. P. J. Weiden and M. Olfson, Cost of relapse in schizophrenia, Schizophr. Bull. 21 (1995) 419-429.10.1093/schbul/21.3.4197481573Search in Google Scholar

17. S. H. Preskorn and D. Flockhart, Guide to psychiatric drug interactions, Prim. Psychiat. 16 (2009) 45-74.Search in Google Scholar

18. I. H. Stockley, Stokley’s Drug Interactions, Pharmaceutical Press, London 2002.Search in Google Scholar

19. A. De Nayer, E. Windhager, I. Irmansyah, I. Larmo, B. Lindenbauer, H. Rittmannsberger, T. Platz, A. Jones, J. Whiteford and C. Altman, Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics, Int. J. Psychiat. Clin. Pract. 7 (2003) 59-66; DOI: 10.1080/13651500310001095.10.1080/1365150031000109524937244Search in Google Scholar

20. P. F. Buckley and C. U. Correll, Strategies for dosing and switching antipsychotics for optimal clinical management, J. Clin. Psychiatry 69 (Suppl. 1) (2008) 4-17.Search in Google Scholar

21. C. U. Correll, Real-life switching strategies with second-generation antipsychotics, J. Clin. Psychiat. 67 (2006) 160-161.10.4088/JCP.v67n012216426102Search in Google Scholar

22. S. Ganesan, V. Agambaram, F. Randeree, I. Eggens, K. Huizar, D. Meuliend and on behalf of 147 investigators, Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia, Curr. Med. Res. Opin. 24 (2008) 21-32; DOI: 10.1185/030079908X253384.10.1185/030079908X253384Search in Google Scholar

23. J. Karagianis, R. Williams, L. Davis, R. Procyshyn, N. Monga, J. Hanley, R. Chandrasena, A. Thakur and R. Dickson, Antipsychotics switching: results from a one-year prospective, observational study of patients with schizophrenia, Curr. Med. Res. Opin. 25 (2009) 2121-2132; DOI: 10.1185/03007990903102966.10.1185/0300799090310296619601707Search in Google Scholar

24. H. C. Lin, M. Y. Chong, Y. Lee, W. C. Yeh and P. Y. Lin, Switching of antipsychotics to aripiprazole in the treatment of schizophrenia, Chang Gung Med. J. 32 (2009) 409-416.Search in Google Scholar

25. D. Taylor, C. Paton and S. Kapur, The Maudsley Prescribing Guidelines in Psychiatry, Wiley Blackwell, Oxford 2015.Search in Google Scholar

26. A. F. Lehman, J. A. Lieberman, L. B. Dixon, T. H. McGlashan, A. Miller, D. O. Perkins and J. Kreyenbuhl, American Psychiatric Association and Steering Committee on Practice Guidelines, Practice guideline for the treatment of patients with schizophrenia, Am. J. Psychiat. 161 (Suppl. 2) (2004) 1-56.Search in Google Scholar

27. J. Bolcato, G. Terrazzani, P. Giusti, T. Walley and A. Chinellato, Atypical antipsychotic prescribing patterns in an Italian district 2001-2009 and the impact of regulatory warnings, Open Sci. J. Clin. Med. 2 (2014) 10-14; DOI: 10.1016/j.pnpbp.2004.06.017.10.1016/j.pnpbp.2004.06.01715588755Search in Google Scholar

28. T. R. Barnes and Schizophrenia Consensus Group of British Association for Psychopharmacology, Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology, J. Psychopharmacol. 25 (2011) 567-620; DOI: 10.1177/0269881110391123. 10.1177/026988111039112321292923Search in Google Scholar

29. A. Hassan, P. Falkai, T. Wobrock, J. Lieberman, B. Glenthoj, W. F. Gattaz, F. Thibaut, H. J. Möller and World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance, World J. Biol. Psychiat. 13 (2012) 318-378; DOI: 10.3109/15622975.2012.696143.10.3109/15622975.2012.69614322834451Search in Google Scholar

30. R. A. Hamilton, L. L. Briceland and M. H. Andritz, Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population, Pharmacotherapy 18 (1998) 1112-1120.Search in Google Scholar

31. C. S. Moura, F. A. Acurcio and N. O. Belo, Drug-drug interactions associated with length of stay and cost of hospitalization, J. Pharm. Pharm. Sci. 12 (2009) 266-272.10.18433/J35C7ZSearch in Google Scholar

32. P. L. Canales, P. G. Dorson and M. L. Crismon, Outcomes assessment of clinical pharmacy services in a psychiatric inpatient setting, Am. J. Health Syst. Pharm. 58 (2001) 1309-1316; DOI: 10.3390/ ijerph111010967.10.1093/ajhp/58.14.130911471478Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo